Trident Texofab Intrinsic Value
Trident Texofab (TTFL) median intrinsic value is ₹21.30 from 8 valuation models (range ₹10–₹63), vs current price ₹31.85 — -33.1% downside (Trading Above Calculated Value), margin of safety -49.5%. For current market price and key ratios, visit TTFL share price.
TTFL Valuation Methods Summary — DCF, Graham Number & P/E
Trident Texofab intrinsic value across 8 models vs current price ₹31.85 — upside/downside and value range per method. Read Trident Texofab dividend policy for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹9.55 | ₹7.64 - ₹11.46 | -70.0% | EPS: ₹0.54, Sector P/E: 12x |
| Book Value Method | asset | ₹37.33 | ₹33.60 - ₹41.06 | +17.2% | Book Value/Share: ₹37.33, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹62.93 | ₹56.64 - ₹69.22 | +97.6% | Revenue/Share: ₹78.67, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹16.00 | ₹14.40 - ₹17.60 | -49.8% | EBITDA: ₹4.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹26.64 | ₹21.31 - ₹31.97 | -16.4% | CF Growth: 14.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹9.55 | ₹8.60 - ₹10.51 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹9.55 | ₹8.60 - ₹10.51 | -70.0% | Revenue Growth: 8.5%, Adj P/E: 8.3x |
| Graham Defensive Method | conservative | ₹21.30 | ₹19.17 - ₹23.43 | -33.1% | EPS: ₹0.54, BVPS: ₹37.33 |
TTFL Intrinsic Value vs Market Price — All Valuation Models
Trident Texofab fair value range ₹10–₹63 vs current market price ₹31.85 across 8 valuation models. Analyse TTFL shareholder distribution to track promoter, FII and institutional holdings.
TTFL Intrinsic Value Analysis — Undervalued or Overvalued?
Trident Texofab median intrinsic value ₹21.30, current price ₹31.85 — Trading Above Calculated Value by 33.1%, margin of safety -49.5%.
What is the intrinsic value of TTFL?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Trident Texofab (TTFL) is ₹21.30 (median value). With the current market price of ₹31.85, this represents a -33.1% variance from our estimated fair value.
The valuation range spans from ₹9.55 to ₹62.93, indicating ₹9.55 - ₹62.93.
Is TTFL undervalued or overvalued?
Based on our multi-method analysis, Trident Texofab (TTFL) appears to be trading above calculated value by approximately 33.1%.
TTFL Financial Health — Key Ratios vs Industry Benchmarks
Trident Texofab financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.33 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 1.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.06x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
TTFL Cash Flow Quality — Operating & Free Cash Flow
Trident Texofab operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-14 Cr | ₹-24 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹6 Cr | ₹6 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹2 Cr | ₹-3 Cr | Positive Operating Cash Flow | 6/10 |